Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I evaluation of sodium stibogluconate in combination with interferon alpha-2b followed by cisplatin, vinblastine and temozolomide for patients with melanoma or malignancies potentially responsive to SSG [sodium stibogluconate] and/or interferons.

Trial Profile

Phase I evaluation of sodium stibogluconate in combination with interferon alpha-2b followed by cisplatin, vinblastine and temozolomide for patients with melanoma or malignancies potentially responsive to SSG [sodium stibogluconate] and/or interferons.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sodium stibogluconate (Primary) ; Cisplatin; Dacarbazine; Dacarbazine; Interferon alpha-2b; Vinblastine
  • Indications Cancer; Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 May 2011 Planned End Date changed from 1 Apr 2012 to 1 Jan 2012.
    • 28 Mar 2011 Planned end date changed from 1 Feb 2009 to 1 Apr 2012 as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top